克服临床 BCR-ABL1 复合突变耐药性的联合 ponatinib 和 asciminib 治疗。
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.
机构信息
Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
出版信息
Cancer Cell. 2024 Sep 9;42(9):1486-1488. doi: 10.1016/j.ccell.2024.08.004. Epub 2024 Aug 29.
Abstract
BCR-ABL1 compound mutations can lead to resistance to ABL1 inhibitors in chronic myeloid leukemia (CML), which could be targeted by combining the ATP-site inhibitor ponatinib and the allosteric inhibitor asciminib. Here, we report the clinical validation of this approach in a CML patient, providing a basis for combination therapy to overcome such resistance.
摘要
BCR-ABL1 复合突变可导致慢性髓细胞白血病 (CML) 对 ABL1 抑制剂产生耐药性，可通过联合使用 ATP 位点抑制剂 ponatinib 和变构抑制剂 asciminib 来靶向这些突变。在此，我们报告了该方法在一名 CML 患者中的临床验证结果，为克服这种耐药性的联合治疗提供了依据。
相似文献
1
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.克服临床 BCR-ABL1 复合突变耐药性的联合 ponatinib 和 asciminib 治疗。
Cancer Cell. 2024 Sep 9;42(9):1486-1488. doi: 10.1016/j.ccell.2024.08.004. Epub 2024 Aug 29.
2
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.联合变构抑制剂 ASCiminib 和 Ponatinib 可抑制高度耐药 BCR-ABL1 突变体的出现并恢复疗效。
Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19.
3
Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.在一名Ph+急性淋巴细胞白血病患者中检测到的一种新的BCR::ABL1 p.I293_K294insSSLRD突变对阿塞西尼布耐药。
Ann Hematol. 2025 Feb;104(2):1117-1126. doi: 10.1007/s00277-024-06142-8. Epub 2025 Jan 7.
4
Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance.ASCIMIB，一种新型的 BCR-ABL1 变构抑制剂，与伊马替尼联合使用时具有协同作用，无论是否存在耐药性。
Pharmacol Res Perspect. 2024 Aug;12(4):e1214. doi: 10.1002/prp2.1214.
5
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.在伴有复合突变的慢性髓性白血病急变期临床前模型中，泊那替尼与阿伐替尼的联合疗法。
Leukemia. 2024 Jun;38(6):1415-1418. doi: 10.1038/s41375-024-02248-0. Epub 2024 Apr 13.
6
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.针对泊那替尼耐药慢性髓性白血病的个性化医疗方法。
Ann Oncol. 2015 Jun;26(6):1180-1187. doi: 10.1093/annonc/mdv110. Epub 2015 Feb 23.
7
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.ASCIMINIB 的特异性，一种治疗慢性髓性白血病的潜在药物，作为一种豆蔻酰口袋结合的 ABL 抑制剂，并分析其与 BCR-ABL1 激酶突变形式的相互作用。
Leuk Res. 2020 Nov;98:106458. doi: 10.1016/j.leukres.2020.106458. Epub 2020 Sep 29.
8
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.BCR-ABL1 复合突变合并关键激酶结构域位置可导致 Ph 染色体阳性白血病对 ponatinib 产生临床耐药性。
Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.
9
BCR-ABL1 compound mutations drive ponatinib resistance.BCR-ABL1 复合突变导致 ponatinib 耐药。
Cancer Discov. 2014 Nov;4(11):OF13. doi: 10.1158/2159-8290.CD-RW2014-186. Epub 2014 Sep 4.
10
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。
N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.
引用本文的文献
1
Advances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia.白血病靶向治疗及其联合策略的进展与挑战
Biomedicines. 2025 Jul 7;13(7):1652. doi: 10.3390/biomedicines13071652.
2
Synergistic effect of asciminib with reduced doses of ponatinib in human Ph + myeloid leukemia with the T315M mutation.阿西替尼与降低剂量的波纳替尼在携带T315M突变的人Ph +髓系白血病中的协同作用。
Int J Hematol. 2025 Apr 10. doi: 10.1007/s12185-025-03981-7.
3
Targeting myeloid cells for hematological malignancies: the present and future.针对血液系统恶性肿瘤的髓系细胞：现状与未来。
Biomark Res. 2025 Apr 10;13(1):59. doi: 10.1186/s40364-025-00775-1.
4
Correspondence to: "Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations", Curik N et al. Leukemia. 2024; 38: 1415-1418.致信：“在伴有复合突变的慢性髓性白血病急变期临床前模型中泊那替尼与阿西替尼的联合治疗”，Curik N等人。《白血病》。2024年；38: 1415 - 1418。
Leukemia. 2025 Mar;39(3):775-778. doi: 10.1038/s41375-025-02521-w. Epub 2025 Feb 6.
5
Novel treatment strategies for chronic myeloid leukemia.慢性髓性白血病的新型治疗策略
Blood. 2025 Feb 27;145(9):931-943. doi: 10.1182/blood.2024026312.
本文引用的文献
1
Management of TKI-resistant chronic phase CML.TKI 耐药慢性期 CML 的治疗管理。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):129-137. doi: 10.1182/hematology.2022000328.
2
Conformational states dynamically populated by a kinase determine its function.构象状态由激酶动态填充，决定其功能。
Science. 2020 Oct 9;370(6513). doi: 10.1126/science.abc2754. Epub 2020 Oct 1.
3
Response and Resistance to BCR-ABL1-Targeted Therapies.BCR-ABL1 靶向治疗的反应和耐药性。
Cancer Cell. 2020 Apr 13;37(4):530-542. doi: 10.1016/j.ccell.2020.03.006.
4
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。
N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.
5
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.联合变构抑制剂 ASCiminib 和 Ponatinib 可抑制高度耐药 BCR-ABL1 突变体的出现并恢复疗效。
Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19.
6
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.为慢性髓性白血病的基于基因组的风险评估奠定基础。
Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17.
7
Toolkit for NMR Studies of Methyl-Labeled Proteins.甲基标记蛋白质的核磁共振研究工具包
Methods Enzymol. 2019;614:107-142. doi: 10.1016/bs.mie.2018.08.036. Epub 2018 Sep 25.
8
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.综合基因组分析揭示了高危疾病患者 CML 诊断时与癌症相关的突变。
Blood. 2018 Aug 30;132(9):948-961. doi: 10.1182/blood-2018-02-832253. Epub 2018 Jul 2.
9
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression .新型变构抑制剂阿伐替尼易受ABCB1和ABCG2过表达介导的耐药影响。
Oncotarget. 2018 Feb 3;9(17):13423-13437. doi: 10.18632/oncotarget.24393. eCollection 2018 Mar 2.
10
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.BCR-ABL1复合突变体对波纳替尼表现出不同的剂量依赖性反应。
Haematologica. 2018 Jan;103(1):e10-e12. doi: 10.3324/haematol.2017.176347. Epub 2017 Oct 5.
Zotero 插件